Race Oncology Limited

ASX:RAC Stock Report

Market Cap: AU$210.2m

Race Oncology Management

Management criteria checks 0/4

Race Oncology's CEO is Daniel Tillett, appointed in Nov 2023, has a tenure of 1.25 years. total yearly compensation is A$1.12M, comprised of 13% salary and 87% bonuses, including company stock and options. directly owns 9.94% of the company’s shares, worth A$20.89M. The average tenure of the management team and the board of directors is 1.2 years and 2.2 years respectively.

Key information

Daniel Tillett

Chief executive officer

AU$1.1m

Total compensation

CEO salary percentage13.0%
CEO tenure1.3yrs
CEO ownership9.9%
Management average tenure1.2yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Aug 26
Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

May 10
We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Jan 23
We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20
Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17
We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14
Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Apr 05
We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

Mar 01
What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Jan 07
How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

CEO Compensation Analysis

How has Daniel Tillett's remuneration changed compared to Race Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$1mAU$145k

-AU$14m

Mar 31 2024n/an/a

-AU$12m

Dec 31 2023n/an/a

-AU$11m

Sep 30 2023n/an/a

-AU$11m

Jun 30 2023AU$836kAU$332k

-AU$10m

Mar 31 2023n/an/a

-AU$10m

Dec 31 2022n/an/a

-AU$11m

Sep 30 2022n/an/a

-AU$11m

Jun 30 2022AU$1mAU$228k

-AU$11m

Mar 31 2022n/an/a

-AU$10m

Dec 31 2021n/an/a

-AU$9m

Sep 30 2021n/an/a

-AU$8m

Jun 30 2021AU$1mAU$167k

-AU$6m

Mar 31 2021n/an/a

-AU$5m

Dec 31 2020n/an/a

-AU$4m

Sep 30 2020n/an/a

-AU$4m

Jun 30 2020AU$147kn/a

-AU$4m

Compensation vs Market: Daniel's total compensation ($USD702.49K) is above average for companies of similar size in the Australian market ($USD284.31K).

Compensation vs Earnings: Daniel's compensation has increased whilst the company is unprofitable.

CEO

Daniel Tillett

1.3yrs

Tenure

AU$1,118,157

Compensation

Dr. Daniel Tillett is Non-Executive Director of Tryptamine Therapeutics Limited from November 8, 2024. Dr. Tillett joined the Tryptamine Therapeutics Limited on November 8, 2024. Dr. Tillett has been Chief...

Leadership Team

NamePositionTenureCompensationOwnership
Peter Smith
Executive Chairman1.7yrsAU$327.72kno data
Daniel Tillett
CEO, Managing Director & Director1.3yrsAU$1.12m9.94%
A$ 20.9m
Michelle Rashford
Chief Medical Officer1.6yrsAU$704.81kno data
Brendan Brown
Chief Financial Officer1.1yrsno datano data
Sophia Moscovis
Vice President of Operations & Strategyless than a yearno datano data
Peter Webse
Company Secretary8.8yrsno datano data

1.2yrs

Average Tenure

Experienced Management: RAC's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Peter Smith
Executive Chairman1.7yrsAU$327.72kno data
Daniel Tillett
CEO, Managing Director & Directorless than a yearAU$1.12m9.94%
A$ 20.9m
Martin Tallman
Member of Scientific Advisory Board8.2yrsno datano data
Douglas Smith
Member of Scientific Advisory Boardno datano datano data
Roland Walter
Member of Scientific Advisory Boardno datano datano data
Borje Andersson
Chairman of Clinical Advisory Board5.2yrsAU$815.36kno data
Jaap-Jan Boelens
Member of Clinical Advisory Board5yrsno datano data
Jianjun Chen
Member of Scientific Advisory Board3.8yrsno datano data
James Breitenbucher
Member of Scientific Advisory Board2.8yrsno datano data
Daniel Hoff
Clinical Advisory Boardless than a yearno datano data
Erin Howden
Member of Scientific Advisory Boardless than a yearno datano data
Serge Scrofani
Independent Non-Executive Directorless than a yearno datano data

2.2yrs

Average Tenure

Experienced Board: RAC's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 15:38
End of Day Share Price 2025/02/07 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Race Oncology Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullIndependent Investment Research (Aust.) Pty Ltd
Chris KallosMST Financial Services Pty Limited